高级检索
当前位置: 首页 > 详情页

The neuroprotection of progesterone against A beta-induced NLRP3-Caspase-1 inflammasome activation via enhancing autophagy in astrocytes

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Dept Clin Pharmacol, Hosp 4, Shijiazhuang, Hebei, Peoples R China [2]Hebei Med Univ, Breast Ctr, Hosp 4, 12 Jiankang Rd, Shijiazhuang, Hebei, Peoples R China [3]Quanzhou Normal Univ, Phys Educ Dept, Quanzhou, Fujian, Peoples R China [4]Bethune Int Peace Hosp, Dept Pharm, Shijiazhuang, Hebei, Peoples R China
出处:
ISSN:

关键词: Alzheimer Neuroinflammation Astrocyte NLRP3 Progesterone Autophagy

摘要:
Neuroinflammation and autophagy dysfunction are known to be involved in the pathological procession of Alzheimer's disease (AD). Progesterone (PG), neuroactive steroids, exerts a characteristic neuroprotective function in improving AD syndrome. The NOD-like receptor pyrin 3 (NLRP3)-Caspase-1 inflammasome has specific relevance to AD pathological procession. However, the exact role of PG in regulating NLRP3-Caspase-1 inflammasome remains to be elucidated. We demonstrated A beta up-regulated IL-1 beta expression in astrocytes by activating NLRP3-Caspase-1 inflammasome. However, pharmacological activation of autophagy by Rapamycin (RAPA) efficiently suppressed A beta-, lipopolysaccharides (LPS)-induced IL-1 beta expression via regulating NLRP3-Caspase-1 inflammasome in astrocytes. Remarkably, PG significantly inhibited A beta-induced NLRP3-Caspase-1 inflammasome activation. Autophagy inhibitor 3-MA blocked the protective effects of PG in mediating NLRP3 inflammasome and IL-1 beta processing. Taken together, our observations suggest that autophagy-lysosome pathway is one specific molecular mechanism in regulating A beta-induced NLRP3-Caspase-1 inflammasome activation in astrocytes, particularly uncover the potential neuroprotection of PG in regulating upstream signaling leading to the sequence events of neuroinflammation. That neuroprotective mechanism of PG in regulating NLRP3-Caspase-1 inflammasome can be a potential therapeutic target for ameliorating the pathological procession of AD.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 3 区 免疫学 3 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 免疫学
JCR分区:
出版当年[2019]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY
最新[2024]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Dept Clin Pharmacol, Hosp 4, Shijiazhuang, Hebei, Peoples R China
通讯作者:
通讯机构: [2]Hebei Med Univ, Breast Ctr, Hosp 4, 12 Jiankang Rd, Shijiazhuang, Hebei, Peoples R China [*1]Breast Center, The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Shijiazhuang, Hebei Province, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号